Patrick Enright is a founder and Managing Director of Longitude Capital. Previously, Mr. Enright was a Managing Director of Pequot Ventures. Prior to Pequot, he was a Managing Member responsible for the Delta Opportunity Fund. Mr. Enright began his investment career at PaineWebber Development Corporation, a direct investment group focused primarily on biotechnology companies. Mr. Enright also has significant life sciences operations experience, including senior executive positions at Valentis, Boehringer Mannheim Pharmaceuticals (now Hoffmann-La Roche) and Sandoz (now Novartis). He currently serves on the boards of CardioDx, Corcept Therapeutics (NASDAQ: CORT), InfaCare Pharmaceuticals, Jazz Pharmaceuticals (NASDAQ: JAZZ) and Xanodyne Pharmaceuticals.
He has previously served on the boards of Codexis (NASDAQ: CDXS), Horizon Therapeutics (acquired), MAP Pharmaceuticals (NASDAQ: MAPP), Prestwick Pharmaceuticals (acquired), Threshold Pharmaceuticals (NASDAQ: THLD) and Sequenom (NASDAQ: SQNM). Mr. Enright holds an MBA from the Wharton School of Business at the University of Pennsylvania and a BS in Biological Sciences from Stanford University.